

RealRate

PHARMACEUTICAL 2019

Cocrystal Pharma Inc. Rank 87 of 363







RealRate

Cocrystal Pharma Inc. Rank 87 of 363

The relative strengths and weaknesses of Cocrystal Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cocrystal Pharma Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 834% points. The greatest weakness of Cocrystal Pharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 122% points.

The company's Economic Capital Ratio, given in the ranking table, is 188%, being 151% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	2,943
Cost of Goods Sold	0
Intangible Assets	65,195
Liabilities, Current	1,557
Liabilities, Non-Current	117
Other Assets	40
Other Compr. Net Income	0
Other Expenses	-13,582
Other Liabilities	0
Other Net Income	294
Other Revenues	0
Property and Equipment	384
Research and Development	58,572
Selling, General and Administrative Expense	4,352

Output Variable	Value in 1000 USD
Assets	68,562
Liabilities	1,674
Expenses	49,342
Revenues	0
Stockholders Equity	66,888
Net Income	-49,048
Comprehensive Net Income	-49,048
Economic Capital Ratio	188%

